Rocket Pharmaceuticals (RCKT) Non-Current Assets (2014 - 2026)
Rocket Pharmaceuticals (RCKT) posted Non-Current Assets of $135.6 million for Q1 2026, down 1.55% sequentially from $137.7 million in Q4 2025, and down 7.5% YoY from $146.6 million in Q1 2025.
Rocket Pharmaceuticals (RCKT) Non-Current Assets (2014 - 2026) Analysis & Trends
Rocket Pharmaceuticals has reported Non-Current Assets for 13 years, with the latest figure at $135.6 million in Q1 2026.
- Quarterly Non-Current Assets fell 7.5% year-over-year to $135.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $557.5 million (down 7.35% YoY) and the FY2025 annual result came in at $137.7 million, down 7.89% from the prior year.
- Non-Current Assets fell to $135.6 million in Q1 2026 per RCKT's latest filing, from $137.7 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $188.1 million in Q4 2023 and troughed at -$445.2 million in Q3 2023.
- A 5-year average of -$22.9 million and a median of $140.4 million in 2025 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2023 and 2024: Non-Current Assets plunged 43.9% in 2023, then soared 149.45% in 2024.
- Over 5 years, Non-Current Assets stood at $187.7 million in 2022, then gained by 0.2% to $188.1 million in 2023, then fell by 20.52% to $149.5 million in 2024, then retreated by 7.89% to $137.7 million in 2025, then declined by 1.55% to $135.6 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $135.6 million, $137.7 million, and $140.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Rocket Pharmaceuticals | 380.92 Mn | 380.92 Mn | - | 133.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 133.55 Mn |
| Mar 31, 2026 | 135.58 Mn |
| Dec 31, 2025 | 137.72 Mn |
| Sep 30, 2025 | 140.35 Mn |
| Jun 30, 2025 | 143.82 Mn |
| Mar 31, 2025 | 146.57 Mn |
| Dec 31, 2024 | 149.52 Mn |
| Sep 30, 2024 | 151.93 Mn |
| Jun 30, 2024 | 153.69 Mn |
| Mar 31, 2024 | 154.28 Mn |
| Dec 31, 2023 | 188.12 Mn |
| Sep 30, 2023 | -445.20 Mn |
| Jun 30, 2023 | -310.81 Mn |
| Mar 31, 2023 | -336.24 Mn |
| Dec 31, 2022 | 187.75 Mn |
| Sep 30, 2022 | -309.38 Mn |
| Jun 30, 2022 | -325.37 Mn |
| Mar 31, 2022 | -352.21 Mn |
| Dec 31, 2021 | -391.33 Mn |
| Sep 30, 2021 | -423.94 Mn |